Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan

Lymphocyte-predominant Hodgkin's lymphoma (LPHL) is known to be radiosensitive, and radiotherapy often forms part of the treatment of patients with stage III or IV LPHL. In addition, as LPHL is thought to arise from a germinal centre B-cell, and LPHL cells express the B-cell marker CD20 there is a rationale for using anti-CD20 therapies for the treatment of LPHL. We report a 42-yr-old man with stage III B LPLH who underwent successful treatment of LPHL with (90)Y-ibritumomab tiuxetan. To our knowledge, this is the first report on the use of an anti-CD20 radiolabeled antibody for the treatment of LPHL.